Aclaris Therapeutics to Participate in Two September Healthcare Conferences
ACRSAclaris Therapeutics to Participate in Two September Healthcare Conferences
August 27, 2025Investor Events
Read more →Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
ACRSAclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 7, 2025Earnings
Read more →Aclaris Therapeutics Has Initiated A Randomized, Double-blind, Placebo-Controlled Phase 2 Trial Of Bosakitug (ATI-045) For Moderate-to-severe Atopic Dermatitis, Top Line Results Expected In The Second Half Of 2026
ACRSJune 2, 2025
Read more →12 Health Care Stocks Moving In Wednesday's Pre-Market Session
ACRSMay 28, 2025
Read more →This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
ACRSMay 28, 2025
Read more →Wedbush Initiates Coverage On Aclaris Therapeutics with Outperform Rating, Announces Price Target of $8
ACRSMay 28, 2025
Read more →HC Wainwright & Co. Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $16
ACRSMay 14, 2025
Read more →Aclaris Therapeutics Q1 EPS $(0.12), Inline, Sales $1.46M Beat $1.28M Estimate
ACRSMay 8, 2025
Read more →Aclaris Therapeutics: FDA Clears IND Application For Phase 1A/1B Clinical Trial Of ATI-052, Bispecific Anti-TSLP/IL-4R Monoclonal Antibody; Co. Expects To Initiate Trial In Q2
ACRSApril 22, 2025
Read more →Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeuticsto Overweight
ACRSMarch 18, 2025
Read more →Scotiabank Initiates Coverage On Aclaris Therapeutics with Sector Outperform Rating, Announces Price Target of $15
ACRSMarch 7, 2025
Read more →Aclaris Therapeutics Expects Cash Runway Into 2028
ACRSFebruary 27, 2025
Read more →Aclaris Therapeutics Q4 2024 GAAP EPS $(1.01) Misses $(0.24) Estimate, Sales $9.21M Beat $2.11M Estimate
ACRSFebruary 27, 2025
Read more →Aclaris Therapeutics Announced The Availability Of A New Publication Describing The Unique Properties Of Aclaris Therapeutics' ATI-2138, A Novel Investigational Covalent Inhibitor Of Interleukin-2-inducible T Cell Kinase And Janus Kinase 3 In Development
ACRSFebruary 12, 2025
Read more →Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy
ACRSHC Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy with a $20 price target. Aclaris gains after licensing agreement with Biosion for potential best-in-class therapies for atopic dermatitis and asthma.
December 23, 2024
Read more →HC Wainwright & Co. Upgrades Aclaris Therapeutics to Buy, Maintains Price Target to $20
ACRSDecember 23, 2024
Read more →Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments
ACRSAclaris secures global rights to Biosion's BSI-045B, advancing trials for atopic dermatitis, asthma, and more. Stock surges on promising updates.
November 19, 2024
Read more →Leerink Partners Upgrades Aclaris Therapeutics to Outperform, Raises Price Target to $7
ACRSNovember 19, 2024
Read more →Jefferies Upgrades Aclaris Therapeutics to Buy, Raises Price Target to $7
ACRSNovember 19, 2024
Read more →BTIG Upgrades Aclaris Therapeutics to Buy, Announces $8 Price Target
ACRSNovember 19, 2024
Read more →Piper Sandler Upgrades Aclaris Therapeutics to Overweight, Raises Price Target to $13
ACRSNovember 18, 2024
Read more →Aclaris Therapeutics Shares Spike Higher; Piper Sandler Upgrades Stock To Overweight With $13 Target Following Biosion Deal; Highlights Pipeline For Atopic Dermatitis And I&I Market, Catalysts Expected In 2025 Trials
ACRSNovember 18, 2024
Read more →Aclaris Therapeutics Secures $80M Through Private Placement Of 35.56M Shares At $2.25 Per Share; Funds To Support Pipeline Development And General Corporate Purposes
ACRSNovember 18, 2024
Read more →Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion For Worldwide Rights (Excluding Greater China) To BSI-045B
ACRSNovember 18, 2024
Read more →Aclaris Had Aggregate Cash, Cash Equivalents And Marketable Securities Of $173.4M As Of September 30, Which Is Expected To Provide Cash Runway Into 2028
ACRSNovember 6, 2024
Read more →Aclaris Therapeutics Q3 2024 GAAP EPS $(0.11) Misses $0.02 Estimate, Sales $4.35M Miss $7.12M Estimate
ACRSNovember 6, 2024
Read more →